High influence of Korean biosimilars, raising expectations

The 3 Korean biosimilars that are currently sold in Europe have been evaluated so positively that market shares of the original products are decreasing. This is why there are high expectations on biosimilars and biobetters which will be launched in the future.

In Korea, the first-approved antibody biosimilar ‘Remsima(infliximab),’ ‘Brenzys(etanercept)’ and ‘Lenflexis(infliximab)’ are already ...